


REMARKS

Claims 1-14, 16-23 and 27-32 are all the claims under consideration in the application. Claims 15, 24, 25 and 26 are cancelled. New Claims 29-32 are added.

A cross-reference to the parent application is added after the title. No new matter is added. New Claims 29-32 recite the subject matter of cancelled Claims 15, 24, 25 and 26, respectively.

Applicants request prosecution of this application on the merits.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'D. R. Kurlandsky', is written over a horizontal line.

David R. Kurlandsky
Reg. No. 41,505
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-7304
Fax (734) 622-1553

Attachment - Amended claims, Version with markings to show changes made

DK1P4439.doc

VERSION WITH MARKINGS TO SHOW CHANGES MADE**IN THE CLAIMS:**

Cancel Claims 15, 24, 25 and 26.

Add the following new Claims 29-32.

Claim 29 (new). A compound according to Claim 5 which is selected from

N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-Diethylaminoethyl)-4-amino-9-fluorenone;

N-Propionyl, N-(2-Diethylaminoethyl)-1-amino-4-bromonaphthalene;

N-Propionyl, N-(N-Morpholino)-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-(3-diethylamino-propyl))-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-Diethylaminoethyl)-1-4-azidonaphthalene;

N-Propionyl, N-(2-Diethylaminoethyl)-3-chlorobenzyl-amine;

N-Propionyl, N-(2-Diethylaminoethyl)-3-bromobenzyl-amine;

N-Propionyl, N-(2-Piperidylethyl)-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-(3-dimethylamino-propyl))-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-Dimethylaminoethyl)-1-amino-4-chloronaphthalene;

N-Propionyl, N-(2-(N-benzyl)-aminoethyl)-1-aminonaphthalene;

N-(2-Diethylamino-ethyl)-N-(7-methyl-quinolin-4-yl)-propionamide;

N-Acryloyl, N-(2-diethylaminoethyl)-1-amino-4-chloronaphthalene; and

N-Propionyl, N-(2-Diethylaminoethyl)-(1-amino-4-nitronaphthalene).

Claim 30 (new). A compound according to Claim 1 which is a pharmaceutically acceptable salt.

Claim 31 (new). A pharmaceutical formulation comprising a compound of Claim 1 together with a pharmaceutically acceptable diluent, carrier or excipient therefor.

Claim 32 (new). A method for treating a CNS disorder in a mammal in need of treatment comprising administering a CNS effective amount of a compound of Claim 1.